CAN008

DRUG3 trials

Sponsors

CANbridge Life Sciences Ltd.

Conditions

GBMGlioblastoma MultiformeNewly-diagnosed Glioblastoma

Phase 1

A Study of CAN008 for Newly Diagnosed Glioblastoma Multiforme

CompletedNCT02853565

CANbridge Life Sciences Ltd.Glioblastoma Multiforme

Start: 2016-08-31End: 2018-09-30Updated: 2018-11-08

Phase 2

To Evaluate the Efficacy and Safety of CAN008 Combined With Re-irradiation (rRT) for Treating Patients With Recurrent Glioblastoma (GBM)

CANbridge Life Sciences Ltd.GBM

Start: 2018-11-20End: 2021-12-31Target: 60Updated: 2018-11-19

Phase 2 Study of CAN008 in Subjects With GBM

CANbridge Life Sciences Ltd.Newly-diagnosed Glioblastoma

Start: 2021-10-10End: 2024-08-31Target: 117Updated: 2022-07-12

Related Papers

Safety and tolerability of asunercept plus standard radiotherapy/temozolomide in Asian patients with newly-diagnosed glioblastoma: a phase I study

Scientific Reports2021-12-159 citations